The estimated Net Worth of Garry Arthur Neil is at least $8.5 Million dollars as of 10 June 2021. Garry Neil owns over 3,692 units of Arena Pharmaceuticals Inc stock worth over $8,136,386 and over the last 8 years he sold ARNA stock worth over $0. In addition, he makes $360,133 as Independent Director at Arena Pharmaceuticals Inc.
Sign up
Garry Neil ARNA stock SEC Form 4 insiders trading
Garry has made over 5 trades of the Arena Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 3,692 units of ARNA stock worth $8,418 on 10 June 2021.
The largest trade he's ever made was buying 2,049,376 units of Arena Pharmaceuticals Inc stock on 5 December 2019 worth over $266,419. On average, Garry trades about 59,263 units every 37 days since 2016. As of 10 June 2021 he still owns at least 81,372 units of Arena Pharmaceuticals Inc stock.
You can see the complete history of Garry Neil stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Garry Neil biography
Dr. Garry A. Neil M.D. serves as Independent Director of the Company. Dr. Neil has served on our Board of Directors since February 2017. Dr. Neil serves as the Chief Scientific Officer of Aevi Genomic Medicine, a publicly held biotechnology company focused on translating genetic discoveries into novel therapies to improve the lives of children and adults with pediatric onset life altering diseases, a position he has held since September 2013. Prior to joining Aevi Genomic Medicine, Dr. Neil was a Partner at Apple Tree Partners, a life science private equity firm, from September 2012 to September 2013, and held a number of senior positions in the pharmaceutical industry, including most recently Corporate VP of Science & Technology at Johnson & Johnson from November 2007 to August 2012. Prior to that, Dr. Neil served as Group President at Johnson & Johnson Pharmaceutical Research and Development, VP of R&D at Merck KGaA/EMD Pharmaceuticals, VP of Clinical Research at AstraZeneca and Astra Merck. Dr. Neil holds a B.S. from the University of Saskatchewan and an M.D. from the University of Saskatchewan College of Medicine. He completed postdoctoral clinical training in internal medicine and gastroenterology at the University of Toronto. Dr. Neil also completed a postdoctoral research fellowship at the Research Institute of Scripps Clinic. He serves on the board of GTx, Inc., a publicly traded biopharmaceutical company focused on cancer and other serious medical conditions. He is the Founding Chairman of TransCelerate Biopharma, Inc., a non-profit pharmaceuticals industry R&D consortium, and remains on its board. He also serves on the board of Reagan Udall Foundation and previously served on the board of Foundation for the National Institutes of Health (NIH) and on the Science Management Review Board of the NIH. He is past Chairman of the Pharmaceutical Research and Manufacturers Association (PhRMA) Science and Regulatory Executive Committee and the PhRMA Foundation Board.
What is the salary of Garry Neil?
As the Independent Director of Arena Pharmaceuticals Inc, the total compensation of Garry Neil at Arena Pharmaceuticals Inc is $360,133. There are 15 executives at Arena Pharmaceuticals Inc getting paid more, with Amit Munshi having the highest compensation of $8,931,400.
How old is Garry Neil?
Garry Neil is 67, he's been the Independent Director of Arena Pharmaceuticals Inc since 2017. There are no older and 14 younger executives at Arena Pharmaceuticals Inc.
What's Garry Neil's mailing address?
Garry's mailing address filed with the SEC is C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 202, HAMPTON, NJ, 08827.
Insiders trading at Arena Pharmaceuticals Inc
Over the last 21 years, insiders at Arena Pharmaceuticals Inc have traded over $9,243,184 worth of Arena Pharmaceuticals Inc stock and bought 78,040 units worth $252,505 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Manmeet Singh Soni und Garry Arthur Neil. On average, Arena Pharmaceuticals Inc executives and independent directors trade stock every 39 days with the average trade being worth of $3,133,387. The most recent stock trade was executed by Amit Munshi on 16 August 2021, trading 1,000 units of ARNA stock currently worth $48,190.
What does Arena Pharmaceuticals Inc do?
Arena Pharmaceuticals, Inc. is a biopharmaceutical company founded in 1997 and located in San Diego, California. The company has small molecule drugs in development for possible clinical utility in multiple therapeutic areas
What does Arena Pharmaceuticals Inc's logo look like?
Complete history of Garry Neil stock trades at Arena Pharmaceuticals Inc, Celldex Therapeutics und Cerecor Inc
Arena Pharmaceuticals Inc executives and stock owners
Arena Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Amit Munshi,
Director, President and Chief Executive Officer -
Vincent Aurentz,
Executive Vice President and Chief Business Officer -
Robert Lisicki,
Executive Vice President and Chief Commercial Officer -
Amit D. Munshi M.B.A.,
Pres, CEO & Director -
Vincent E. Aurentz,
Exec. VP & Chief Bus. Officer -
Dr. Christopher H. Cabell FACC, M.D., MHS,
Advisor -
Laurie D. Stelzer,
Exec. VP & CFO -
Joan Schmidt,
Exec. VP, Gen. Counsel & Sec. -
Tina Nova,
Independent Chairman of the Board -
Jennifer Jarrett,
Independent Director -
Randall Woods,
Independent Director -
Jayson Dallas,
Independent Director -
Manmeet Soni,
Independent Director -
Kieran Gallahue,
Independent Director -
Oliver Fetzer,
Independent Director -
Garry Neil,
Independent Director -
Katharine Knobil,
Director -
Joan Schmidt,
Executive Vice President, General Counsel, Secretary -
Laurie Stelzer,
Chief Financial Officer, Executive Vice President -
Patrick Malloy,
VP of Investor Relations & Corp. Communications -
Megan E. Knight,
Director of Investor Relations -
Dr. Lamine Mbow Ph.D.,
Sr. VP & Chief Scientific Officer -
Dr. Douglas A. Bakan Ph.D.,
Exec. VP of Technical Operations -
Harry F Jr Hixson,
Director -
Maurice James Mezzino,
SVP, Corporate Development -
Phillip M Schneider,
Director -
Preston Klassen,
EVP and CMO -
Steven W Spector,
EVP, General Counsel & Sec -
Scott H Bice,
Director -
Kevin Robert Lind,
Executive VP and CFO -
Christine Anna White,
Director -
Donald D Belcher,
Director -
Nawal Ouzren,
Director -
Frederick Frank,
-
Mark N Lampert,
Director -
Robert Hoffman,
SVP, Finance and CFO -
Partners L P/Ilbiotechnolog...,
-
James Laforce,
Director -
Jennifer Kathleen Bielasz,
VP, Accounting & Controller -
K A Ajit Simh,
VP, Quality Systems -
Jack Lief,
Chairman, President and CEO -
Craig Michael Audet,
SVP, Opn & Head Glob Reg Afrs -
Duke K Bristow,
Director -
Robert L Toms,
Director -
Paul W Maffuid,
VP, Pharmaceutical Development -
Joyce H Williams,
VP, Drug Development -
Partners L P/Ilbvf Inc/Ilbi...,
-
Nigel R A Beeley,
VP, Chief Chemical Officer -
Joseph F Mooney,
Chief Financial Officer -
Derek T Chalmers,
Vice President, Research -
Louis J Scotti,
VP, Marketing and Bus Dev -
Dominic P Behan,
EVP & Chief Scientific Officer -
James Edeerfield Capital Lp...,
-
Louis J Jr Lavigne,
Director -
William R Jr Shanahan,
SVP & Chief Medical Officer -
Christopher Cabell,
EVP, Head of R&D, and CMO -
Steven J Schoch,
Director -
Douglas J. Manion,
EVP Research & Development